Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2016

01-02-2016 | The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Modeling and Cost-Effectiveness in HIV Prevention

Authors: Margo M. Jacobsen, Rochelle P. Walensky

Published in: Current HIV/AIDS Reports | Issue 1/2016

Login to get access

Abstract

With HIV funding plateauing and the number of people living with HIV increasing due to the rollout of life-saving antiretroviral therapy, policy makers are faced with increasingly tighter budgets to manage the ongoing HIV epidemic. Cost-effectiveness and modeling analyses can help determine which HIV interventions may be of best value. Incidence remains remarkably high in certain populations and countries, making prevention key to controlling the spread of HIV. This paper briefly reviews concepts in modeling and cost-effectiveness methodology and then examines results of recently published cost-effectiveness analyses on the following HIV prevention strategies: condoms and circumcision, behavioral- or community-based interventions, prevention of mother-to-child transmission, HIV testing, pre-exposure prophylaxis, and treatment as prevention. We find that the majority of published studies demonstrate cost-effectiveness; however, not all interventions are affordable. We urge continued research on combination strategies and methodologies that take into account willingness to pay and budgetary impact.
Literature
1.
UNAIDS and Kaiser Family Foundation. Financing the response to HIV in low- and middle-income countries: international assistance from donor governments in 2014. July 2015.
2.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8.CrossRefPubMed
3.
Chambers JD, Cangelosi MJ, Neumann PJ. Medicare’s use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy. 2015;119(2):156–63.CrossRefPubMed
4.
Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. World Health Organization. 2001.
5.
6.
National Treasury of the Republic of South Africa. Estimates of national expenditure (Abridged version). 2015.
7.
Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb D, et al. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: are current international norms fit for purpose? [CHE Research Paper 98]. The University of York: Center for Health Economics. 2014.
8.
Uthman OA, Popoola TA, Uthman MM, Aremu O. Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review. PLoS One. 2010;5(3), e9628.CrossRefPubMedPubMedCentral
9.
Menon V, Gold E, Godbole R, Castor D, Mahler H, Forsythe S, et al. Costs and impacts of scaling up voluntary medical male circumcision in Tanzania. PLoS One. 2014;9(5), e83925.CrossRefPubMedPubMedCentral
10.
Pham QD, Wilson DP, Kerr CC, Shattock AJ, Do HM, Duong AT, et al. Estimating the cost-effectiveness of HIV prevention programmes in Vietnam, 2006–2010: a modelling study. PLoS One. 2015;10(7), e0133171.CrossRefPubMedPubMedCentral
11.••
Mitchell KM, Lepine A, Terris-Prestholt F, Torpey K, Khamofu H, Folayan MO, et al. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS. 2015;29(15):2035–44. This study examined TasP, short- vs. long-term PrEP, condom promotion, and several combinations of these strategies using a deterministic cohort model. The results indicate the order in which prevention interventions should be prioritized as more resources become available.CrossRefPubMedPubMedCentral
12.
Mvundura M, Nundy N, Kilbourne-Brook M, Coffey PS. Estimating the hypothetical dual health impact and cost-effectiveness of the woman’s condom in selected sub-Saharan African countries. Int J Womens Health. 2015;7:271–7.PubMedPubMedCentral
13.
United Nations Population Fund, Global Forum on MSM & HIV, United Nations Development Programme, World Health Organization, United States Agency for International Development, World Bank. Implementing comprehensive HIV and STI programmes with men who have sex with men: practical guidance for collaborative interventions. 2015.
14.
Ruger JP, Abdallah AB, Ng NY, Luekens C, Cottler L. Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial. AIDS Behav. 2014;18(10):1913–23.CrossRefPubMed
15.
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States. PLoS One. 2015;10(2), e0116694.CrossRefPubMedPubMedCentral
16.•
Vassall A, Pickles M, Chandrashekar S, Boily MC, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in South India. Lancet Glob Health. 2014;2(9):e531–40. Using a dynamic transmission model, Vassall et al. estimate the number of HIV infections, DALYs averted, and incremental cost-effectiveness of a prevention program implemented at scale across 22 different districts in India. This study is a good example of how intervention costs and effectiveness can vary substantially within a single country, with program costs/DALY averted ranging from $17–$472 between districts.CrossRefPubMed
17.
Vassall A, Chandrashekar S, Pickles M, Beattie TS, Shetty G, Bhattacharjee P, et al. Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysis. PLoS One. 2014;9(10), e110562.CrossRefPubMedPubMedCentral
18.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. June 2013.
19.
VanDeusen A, Paintsil E, Agyarko-Poku T, Long EF. Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana. BMC Infect Dis. 2015;15:130.CrossRefPubMedPubMedCentral
20.
Gopalappa C, Stover J, Shaffer N, Mahy M. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV. AIDS. 2014;28 Suppl 1:S5–14.CrossRefPubMed
21.
Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Mwango A, Ghidinelli MN, et al. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia. PLoS One. 2014;9(3), e90991.CrossRefPubMedPubMedCentral
22.
Yu W, Li C, Fu X, Cui Z, Liu X, Fan L, et al. The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling. PLoS One. 2014;9(7), e102872.CrossRefPubMedPubMedCentral
23.
Long EF, Mandalia R, Mandalia S, Alistar SS, Beck EJ, Brandeau ML. Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom. PLoS One. 2014;9(4), e95735.CrossRefPubMedPubMedCentral
24.
Hutchinson AB, Farnham PG, Sansom SL, Yaylali E, Mermin JH. Cost-effectiveness of frequent HIV testing of high risk populations in the United States. J Acquir Immune Defic Syndr. 2015.
25.••
Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. J Infect Dis. 2015;212(4):570–7. Using a stochastic, individual-based model, a scenario of no self-testing is compared to a scenario with self-testing. Although self-testing has only a modest impact on health or savings, the authors posit that the money saved through self-testing could be further invested in other highly cost-effective intervention. This optimistic point of view is one policy makers can keep in mind when considering healthcare savings.CrossRefPubMedPubMedCentral
26.
Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, et al. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV. 2015;2(4):e159–68.CrossRefPubMedPubMedCentral
27.
Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One. 2014;9(1), e85197.CrossRefPubMedPubMedCentral
28.
Owusu-Edusei Jr K, Tao G, Gift TL, Wang A, Wang L, Tun Y, et al. Cost-effectiveness of integrated routine offering of prenatal HIV and syphilis screening in China. Sex Transm Dis. 2014;41(2):103–10.CrossRefPubMed
29.
Rutstein SE, Brown LB, Biddle AK, Wheeler SB, Kamanga G, Mmodzi P, et al. Cost-effectiveness of provider-based HIV partner notification in urban Malawi. Health Policy Plan. 2014;29(1):115–26.CrossRefPubMedPubMedCentral
30.
Birnkrant D. Truvada® (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) for HIV-1 prevention in populations at high risk of sexually acquired HIV Infection NDA 21752 S-30. Antiviral Products Advisory Committee, U.S. Food and Drug Administration. 2012.
31.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
32.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
33.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
34.
Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
35.
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
36.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
37.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedPubMedCentral
38.
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.CrossRefPubMedPubMedCentral
39.
Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3), e1001401.CrossRefPubMedPubMedCentral
40.
Schackman BR, Eggman AA. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS. 2012;7(6):587–92.CrossRefPubMed
41.
Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541–50.CrossRefPubMedPubMedCentral
42.
Kessler J, Myers JE, Nucifora KA, Mensah N, Toohey C, Khademi A, et al. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York City. AIDS. 2014.
43.
Chen A, Dowdy DW. Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making. PLoS One. 2014;9(10), e108742.CrossRefPubMedPubMedCentral
44.
Schneider K, Gray RT, Wilson DP. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin Infect Dis. 2014;58(7):1027–34.CrossRefPubMed
45.
Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9(1), e86584.CrossRefPubMedPubMedCentral
46.
Mabileau G, Schwarzinger M, Flores J, Patrat C, Luton D, Epelboin S, et al. HIV-serodiscordant couples desiring a child: ‘treatment as prevention,’ preexposure prophylaxis, or medically assisted procreation? Am J Obstet Gynecol. 2015;213(3):341.e1–e12.CrossRef
47.•
Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, Delany-Moretlwe S, et al. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014;14:14. This study determines the cost and cost-effectiveness of gel-based HIV prophylaxis used on a per-sex act basis, a substantially less expensive option than daily oral PrEP. The authors perform analyses to determine the various cost, coverage, and effectiveness thresholds that would be required for the gel to be considered as cost-effective as condoms. This unique analysis is useful for comparison of prevention interventions.CrossRefPubMedPubMedCentral
48.
Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.CrossRefPubMedPubMedCentral
49.
Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc. 2015;18(4 Suppl 3):20013.PubMedPubMedCentral
50.
Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, et al. Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One. 2015;10(1), e0115511.CrossRefPubMedPubMedCentral
51.
52.
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54(10):1504–13.CrossRefPubMedPubMedCentral
53.••
Nichols BE, Baltussen R, van Dijk JH, Thuma PE, Nouwen JL, Boucher CA, et al. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr. 2014;66(2):221–8. The authors utilize stochastic league tables, an approach that calculates the probability of selecting an intervention based on different budget levels. This method is exceptionally important for policy makers who must consider budgeting and what interventions to fund.PubMed
54.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral
55.
Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRefPubMed
56.
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRefPubMed
57.•
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715–25. Based on the results of HPTN052, this study was the first to report that TasP is a cost-effective prevention strategy for serodiscordant couples, with results supporting this conclusion both in a South African and Indian context. Several studies have since gone on to evaluate the cost-effectiveness of TasP in various countries and populations.CrossRefPubMedPubMedCentral
58.
Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser-Hurt N, Benedikt C, et al. Optima: a model for HIV epidemic analysis, program prioritization, and resource optimization. J Acquir Immune Defic Syndr. 2015;69(3):365–76.CrossRefPubMed
59.
60.
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005;25(3):321–9.CrossRefPubMed
Metadata
Title
Modeling and Cost-Effectiveness in HIV Prevention
Authors
Margo M. Jacobsen
Rochelle P. Walensky
Publication date
01-02-2016
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2016
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0303-2

Other articles of this Issue 1/2016

Current HIV/AIDS Reports 1/2016 Go to the issue

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Friend or Foe: Innate Sensing of HIV in the Female Reproductive Tract

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Broadly Neutralizing Antibodies for HIV Eradication

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Novel Imaging Methods for Analysis of Tissue Resident Cells in HIV/SIV

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits